You asked and we delivered.
Earlier this week, OXIS announced that they will be holding an investor conference call on Tuesday, March 31, 2015 at 4:15pm EST to discuss recent corporate developments. Well, we immediately started receiving emails and social media messages from our loyal followers as to who will be hosting the conference call and how you could ask specific questions. It is clear that OXIS has been receiving a lot of attention since we first published our “Connect the Dots” piece on January 12, 2015, as the share price has risen approximately 140% hitting a high of $0.06 in March and rightfully so with the announcements coming out of this company over the last three months.
We reached out to OXIS CEO Tony Cataldo and expressed the amount of interest our followers have in the upcoming conference call and asked if we could moderate the call. Mr. Cataldo replied with,
“I would love to have MarijuanaStocks.com host our investor call. We have some very exciting things to share with our stakeholders as we look forward to a promising 2015 and are glad to see a community as large as MarijuanaStocks.com show such interest in what we are doing.”
Your voices have been heard! We invite every single one of you to email us the questions that you want to ask Tony Cataldo to oxis@marijuanastocks.com. Or message us on Facebook or Twitter @MarijuanaStocks or @WolfofWeedSt. We will do our very best to represent our followers and ask every question we receive, within reason. You have until Monday, 4pm EST to submit your question(s) for the Tuesday call.
To listen to the call live:
Dial-in Number: 712.775.7031
Meeting ID Number: 576-591-822
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
16 comments
Awesome! I’m dying to know if Cataldo is getting blown up by the old LBIO funders and banks bc LBIO is a rockstar. I would have to imagine that the same guys that gave him money for LBIO are ready to cut him another fat check for OXIS.
I would have to imagine so right? The volume and price have been going strong lately. I would want to know more about where the company’s looking to focus on for Q2. Are they still looking into focus on myeloma or will they in fact explore further things like breast cancer or even other applications for therapies outside of cancer?
I want to know if Cataldo thinks having Dr. Mule on board will speed up their FDA trial process when that time comes given he is an employee of the FDA. What kind of pull does this guy have and how will Cataldo take advantage of it?
I would like to hear and see some more detailed data on the drugs they’re working on.
I would like to as well and then I’d also like to here how everything weighs in on bringing things to market, phase trials, etc.
Cataldo has made major strides since becoming CEO. But I am eager to find out what’s next in store for OXIS. Ever since they executed the worldwide exclusive patent licensing, the stock’s trading has really taken off. I would just like to know what’s next so I don’t fall into the hype of biotech/cannabis focus stocks.
Im curious to see where he will take OXIS in the next 6 months?
It’s amazing to know the strides that were made when Mr. Cataldo was the Chairman /CEO of LBIO are substantial to further the progression of OXIS. Im excited to hear this press conference to see what unfolds for OXIS.
What is a reasonable timetable for OXIS patent approval?
I would like to know what price target before selling them Tony would like to give his own shares and if the company can keep track of the difference in number of listed shares on Euronext and the OTC market.
Due to the ticksize of €0,01 and the huge number of shares (30 million on each €0,01 price increment in Europe), it seems impossible for the shares to make any further moves in share price.
When will oxis update its website with information about drugs, patents, technologies, etc? Almost all links are under construction.
tony veut que le prix de l’action monte jusqu’ou??
hello, I want to know is how he sees or wants to raise the share value Oxis
Some question about ergothioneine:
Since 2010 Oxis “is testing” some products containing ergothioneine, what can you say about the marketing of products using ergothioneine (Ergoflex, Reverge, Prograce …)? In the last 10Q 2014 you says “As of 2014, we are Evaluating the marketability of this product.”
What about ERGO-ARDS research with Dr. Repine?
Can you give us details of the dispute with Nexdius?
“On October 24, 2014, the Company reached a satisfactory resolution with Nexdius PTY LTD and Exposure Scientific, LLC.For consideration of releasing Nexdius and Exposure Scientific from any further claims, the Company will receive a cash payment and perpetual royalty against all future product sales.”
Can you give us details of the dispute with Estee Lauder in 2010? No cash payment and no royalty for the license granted to Estee Lauder?
Some question about Oxis biotech :
Tell us about the two main drug candidates (OXS-2175 and 4235-OXS).
You have two lead drug candidates (OXS-2175 and OXS-4235) in optimization phase, for when do you begin a Phase 1?
other questions:
What should be the maximum number of shares authorized to regularize the situation with the convertible debt and warrants?
How should you take decisions regarding the number of shares authorized by August 14, 2015?
A reverse stock split is it relevant?
Concerning the regulatory path, does Oxis International believe the easing of the adaptive pathway approach from the EMA is a more appealing path to market than the FDA route? If so, can you discuss a timeline that would be utilized, or what shareholders can expect from either of those environments?
Hello,
As every shareholders having shares from OXIS on the Euronext market,I saw today that the quotation is suspended:
“We are taking this time to consider the value to our shareholders of Oxis shares trading in multiple markets. Our plans for OXIS shareholders trading abilities this year, incorporates our desire to up list to a NASDAQ National Market listing as we continue to bring in high value biotech assets to Oxis Biotech, Inc. Management will make a decision on the resumption of trading on the Euronext after the evaluation period has ended. We want all shareholders to know the suspension is an Oxis corporate decision”
And we see that at the same time, the shares are still quoted on the OTCQB in the US and on the Frankfurt market.
Then my question is:
WHEN the quotation is supposed to restart on Euronext? I mean, is it supposed to be a short suspension or a month one?? Will it be quoted as it was untill now, with only 2 digits after the dot(zero)?
Are the shares actually in quotation on Euronext supposed to be tradable too on the US market? Do you plane a reverse split?
Thanks in advance for the most clear explanation as possible…regards
Hello,
As every shareholders having shares from OXIS on the Euronext market,
I saw today that the quotation is suspended:
“We are taking this time to consider the value to our shareholders of Oxis shares trading in multiple markets. Our plans for OXIS shareholders trading abilities this year, incorporates our desire to up list to a NASDAQ National Market listing as we continue to bring in high value biotech assets to Oxis Biotech, Inc. Management will make a decision on the resumption of trading on the Euronext after the evaluation period has ended. We want all shareholders to know the suspension is an Oxis corporate decision”
And we see that at the same time, the shares are still quoted on the OTCQB in the US and on the Frankfurt market.
Then my question is:
When the quotation is supposed to restart on Euronext? I mean, is it supposed to be a short suspension or a month one?? Will it be quoted as it was untill now, with only 2 digits after the dot(zero)?
Are the shares actually in quotation on Euronext supposed to be tradable too on the US market? Do you plane a reverse split?
Thanks in advance for the most clear explanation as possible…regards